Centre Hospitalier Universitaire Sainte-Justine
Montreal, QC CA
Centre Hospitalier Universitaire Sainte-Justine Patent applications | ||
Patent application number | Title | Published |
---|---|---|
20130065238 | SYNGAP1 DYSFUNCTIONS AND USES THEREOF IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS FOR MENTAL RETARDATION - The invention identifies Syngap1 dysfunctions as causative of mental retardation. Described are methods of detecting mental retardation and methods of detecting non-syndromic mental retardation (NSMR) in a human subject. Particular methods comprise sequencing a human subject's genomic DNA for comparison with a control sequence from an unaffected individual. Also described are probes, kits, antibodies and isolated mutated Syngap1 proteins. | 03-14-2013 |
20110144014 | CYTOKINE RECEPTOR MODULATORS AND USES THEREOF - The present invention relates to cytokine receptor-binding compounds, such as non-competitive VEGF receptor, IL-1 receptor, IL-4 receptor, or IGF-1 receptor-binding peptides and petidomimetic antagonists, and therapeutic uses of such compounds. The compounds of the present invention may be used in the treatment of cytokine-associated diseases such as proliferative disorders (for example, colon, breast, prostate, and lung cancer), abnormal neovascularization and angiogenesis, age-related macular degeneration, and proliferative and/or inflammatory skin disorders such as psoriasis. | 06-16-2011 |
20110135661 | TREATMENT AND PREVENTION OF DRY AGE-RELATED MACULAR DEGENERATION BY ACTIVATING CD36 - The present invention relates to methods and compositions for the prevention and/or treatment of dry age-related macular degeneration by administering a CD 36-activator compound to a subject in need thereof; wherein the CD36 activator compound is the CD36 antibody FA6-152, or the growth hormone (GH)-releasing peptide family-derived compound EP80317 or the compound of Formula 1 [A-(Xaa) | 06-09-2011 |